Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 07, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 740,000 Ordinary shares of 25 pence each.
- Purchase Date: September 07, 2005.
- Purchase Price: 1,363.808 pence per share.
- Treasury Holdings Post-Purchase: 110,983,000 shares.
- Shares in Issue (excluding Treasury): 5,833,914,492 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 740,000 share repurchase based on the disclosed price of 1,363.808 pence.
- Confirm the updated total share count (5,833,914,492 in issue) against subsequent filings.
- Review the remaining authorization limit for share buybacks under the May 25, 2005 shareholder resolution.